Clinical trial
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
NCT00403169 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00403169 |
|---|---|
| Title | Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer |
| Official title | Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC) |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | lenalidomide |
| Enrollment | 26 |
| Start date | Aug 1, 2004 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Nov 23, 2006 |
| Last update posted | Apr 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: